Wednesday, January 23, 2019
LeMaitre price target lowered to $24 from $30 at Lake Street
Lake Street analyst Brooks O’Neil lowered his price target for LeMaitre Vascular to $24 and maintains a Hold rating on the shares. Toward the end of 2018, LeMaitre backed away from its long-term guidance for 10% revenue growth and 20% earnings growth, O’Neil tells investors in a research note.
https://thefly.com/landingPageNews.php?id=2852373
eHealth price target raised to $60 from $50 at SunTrust
SunTrust analyst Tobey Sommer raised his price target on eHealth to $60 and kept his Buy rating after its preliminary Q4 results, saying the company generated “strong growth” in Medicare applications submitted online of over 22% vs. 10% in Q3. The analyst adds that eHealth is benefiting from a “robust” Medicare annual enrollment period, noting that his positive longer term view is further supported by the company’s “highly scalable” opportunity for accelerating organic growth.
https://thefly.com/landingPageNews.php?id=2852395
Bausch Health Introduces Zen Multifocal Scleral Lens for Presbyopia
Bausch + Lomb, a leading global eye health company, today announced the introduction of the Zen(TM) Multifocal scleral lens for Presbyopia, which will be exclusively available with Zenlens(TM) and Zen(TM) RC scleral lenses through the company’s Specialty Vision Products unit. This latest innovation will allow eye care professionals to fit presbyopic patients who have irregular and regular corneas, as well as those who suffer from ocular surface disease, such as dry eye, with ADD power ranges from +1.00 to +3.50 diopter (D) in 0.25D steps.
Building upon the Zenlens and Zen RC scleral lens technology, the new Zen multifocal scleral lens incorporates decentered optics, enabling the near power to be positioned over the visual axis. The multifocal design also offers variable near zones from 1.5 mm to 3.0 mm in 0.5 mm steps.
“The Zen Multifocal scleral lens was developed to address the unique vision needs of presbyopic patients,” said Jason Jedlicka, O.D., FAAO, FSLS, FCLSA, associate professor and director of the Cornea and Contact Lens Service, Indiana University School of Optometry. “By aligning the multifocal optics over the visual axis, which in soft multifocal contact lenses has been shown to provide patients with clear vision over near, intermediate and far distances1, the Zen Multifocal design is well-suited for a wide range of customized presbyopic lens wearers.”
With the Zen Multifocal design, eye care practitioners can continue using the current Zenlens or Zen RC diagnostic sets when fitting patients. The Zenlens and Zen RC are customized scleral lenses that were designed to meet the needs of specialty vision patients and eye care professionals fitting a wide variety of corneal shapes and sizes. Both lenses use SmartCurve(TM) technology, which allows eye care professionals to simplify fittings by modifying only the parameter they need.
JPMorgan downgrades Apellis to Neutral with no data until Q4
JPMorgan analyst Anupam Rama downgraded Apellis Pharmaceuticals to Neutral from Overweight with an unchanged price target of $34. The analyst continues to like the shares long term and view APL-2 as an underappreciated asset in the complement space. However, with data not out until Q4, the analyst expects Apellis shares to perform in line with the market in the first half of 2019.
https://thefly.com/landingPageNews.php?id=2852307
JPMorgan double downgrades Dova on ‘underwhelming’ Doptelet launch
JPMorgan analyst Anupam Rama double downgraded Dova Pharmaceuticals to Underweight from Overweight and cut his price target for the shares to $20 from $34. While the analyst continues to view Doptelet “as a largely de-risked asset from a clinical standpoint,” he believes focus in the near term will be on the launch in chronic liver disease, which he says “has underwhelmed thus far.” Further, Rama thinks it may take several quarters for new management to put into motion a revised strategy. As such, he thinks Dova shares will underperform in the first half of 2019.
https://thefly.com/landingPageNews.php?id=2852317
Eidos Therapeutics downgraded to Neutral from Overweight at JPMorgan
Eidos Therapeutics downgraded to Neutral from Overweight at JPMorgan. JPMorgan analyst Rama downgraded Eidos Therapeutics to Neutral from Overweight with an unchanged price target of $29. The analyst continues to believe AG10 “will emerge as a best in class stabilizer with time,” but he views 2019 as “more of an execution year.” Eidos shares will be a “relative Neutral” in the first half of 2019 while remaining attractive for investors with a multi-year horizon, says Rama.
https://thefly.com/landingPageNews.php?id=2852323
Subscribe to:
Posts (Atom)